Lenire effectiveness for tinnitus underlined by new real world data

Bimodal neuromodulation is the simultaneous stimulation of two nerves for therapeutic purposes, and in the interest of providing relief for sufferers of Tinnitus, a product called Lenire plays audio tones via headphones while delivering mild energy pulses to the surface of the tongue. Produced by Neuromod Devices, a global medical technology company with offices in Ireland and the USA, the technique had already shown fine results in propietary large-scale trials.

Now, a new study published in Nature Communications Medicine has come along and confirmed these good results in real-world testing. An analysis of 220 patients makes the research one of the largest real-world analyses of tinnitus patients ever published in a peer-reviewed scientific journal. The paper, entitled Retrospective chart review demonstrating effectiveness of bimodal neuromodulation for tinnitus treatment in a clinical setting reported 91.5% of tinnitus patients had a clinically significant reduction in tinnitus.

Lenire has not been around long, having been granted De Novo approval by the FDA in March 2023. Under the care of an audiologist with tinnitus expertise, patients typically use the device at home for two 30-minute sessions daily for an average of 12 weeks.

“To achieve real-world positive results that are better than what were observed in our previous controlled clinical trial that led to FDA authorization for the Lenire treatment is a major advancement for the tinnitus field,” said Neuromod Chief Scientific Officer and University of Minnesota Professor, Hubert Lim, Ph.D. “Publication of Lenire’s real-world data in a top-tier scientific journal further validates Lenire’s bimodal neuromodulation as a treatment option for tinnitus patients.”

Source: PR Newswire